Seeking Alpha

Keryx Pharmaceuticals (KERX) +12.4% premarket, enjoying a boost from two analyst buy...

Keryx Pharmaceuticals (KERX) +12.4% premarket, enjoying a boost from two analyst buy recommendations. Ladenburg Thalmann notes data from the long-term Phase 3 study of hyposphatemia drug Zerenex (data expected in Q4) represents a "significant event" for KERX. Roth Capital raises its target price on the shares to $7 from $4.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|